All In Biotech

Free tool

FAERS Monitor: Yutiq

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210331 or its brand name (Yutiq, Fluocinolone Acetonide). Reports on generic versions are filed under their own applications.

Reports

2,444

Serious

757

31% of reports

Hospitalization

274

Death reported

42

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use519
  • product dose omission issue199
  • drug ineffective187
  • pruritus166
  • rash143
  • no adverse event130
  • diarrhoea115
  • psoriasis95
  • headache90
  • fatigue89
  • pain85
  • nausea81
  • dermatitis atopic80
  • product use in unapproved indication73
  • dry skin71

Reports by year received

View as table
YearReports
20048
200514
20067
200711
20089
200915
201017
201128
201232
201317
201426
201553
201675
201766
201873
2019115
2020163
2021174
2022286
2023190
2024585
2025295
2026185

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,715 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
dermatitis atopicSignal8013.110.5881
psoriasisSignal956.35.1417
no adverse eventSignal1306.25.2564
product dose omission issueSignal1995.85.1802
off label useSignal5195.14.71,781
dry skinSignal714.63.6196
pruritusSignal1663.73.2333
rashSignal1432.82.4170
product use in unapproved indicationSignal732.52.067
diarrhoea1151.51.321
headache901.21.04
drug ineffective1871.21.18
pain851.21.02
fatigue891.00.80
nausea810.90.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.